Phase 4
Completed N=44
Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration
Retinal Degenerations
Source: ClinicalTrials.gov NCT00716586 ↗
Enrolled (actual)
44
Serious AEs
0.0%
Results posted
Oct 2021
Primary outcomePrimary: Number of Participant With Improvement in Foveal Thickness (Macular Fluid) as Measured by Optical Coherence Tomography (OCT) — 36 participants
◆ Published Evidence
Established
56citations · ~3 / year
Relation of response to treatment with dorzolamide in X-linked retinoschisis to the mechanism of functional loss in retinoschisin.
Summary
A small percentage of patients with retinal degeneration accumulate fluid in the center of their retina.
Previous studies using an oral form of treatment has been successful in decreasing this fluid which improves vision.
This study will test the use of a topically applied form of this treatment to the eye to reduce the amount of fluid and improve or preserve vision.
Linked Publications
-
Relation of response to treatment with dorzolamide in X-linked retinoschisis to the mechanism of functional loss in retinoschisin.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participant With Improvement in Foveal Thickness (Macular Fluid) as Measured by Optical Coherence Tomography (OCT) |
36 | — |
| PRIMARY Number of Participants With Improvement in Macular Fluid as Measured Subjectively by Optical Coherence Tomography (OCT) |
36 | — |
| SECONDARY Number of Participants With Improvement of Seven Letters or More Read on a Visual Chart |
20 | — |
Eligibility Criteria
Inclusion Criteria
- Presence of cystic macular fluid on OCT testing
Exclusion Criteria
- Allergic reaction to sulpha containing compounds
- Intolerance to dorzolamide (Trusopt)
Data sourced from ClinicalTrials.gov (NCT00716586) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.